AKT1 and early-onset autosomal dominant Alzheimer disease: Molina-Salinas et al. have shown that PRL can inhibit glutamate excitotoxicity through the AKT and STAT5 pathways, thereby protecting neuronal cells and decreasing the progression of Alzheimer’s disease (Molina-Salinas et al., 2021).